글로벌 골감소증 치료 시장 – 2031년까지의 산업 동향 및 예측

골다공증 치료 시장 분석 및 규모

골감소증 치료에 대한 글로벌 시장은 특히 전 세계 노령 인구 사이에서 골밀도 장애에 대한 인식과 진단이 증가함에 따라 주도되고 있습니다. 골감소증은 골다공증의 전조이기 때문에 조기 개입과 예방에 초점을 맞춘 의료 이니셔티브가 두드러지고 있습니다. 시장 성장은 뼈 건강을 조기에 감지하고 모니터링할 수 있는 진단 기술의 발전으로 더욱 촉진되고 있습니다. 치료 전략에는 비스포스포네이트, 호르몬 요법 및 뼈 밀도를 높이는 것을 목표로 하는 기타 약물을 포함한 다양한 약물 옵션이 포함됩니다. 또한, 식이 보충제, 운동 요법 및 칼슘/비타민 D 보충제와 같은 라이프스타일 수정은 골감소증 관리에 중요한 역할을 합니다.         

글로벌 골감소증 치료 시장 규모는 2023년에 147억 7천만 달러로 평가되었으며, 2031년까지 206억 8천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 4.3%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

Market Definition

Osteopenia treatment refers to medical interventions aimed at managing and potentially reversing lower-than-normal bone density, which characterizes osteopenia. This condition is considered a precursor to osteoporosis, where bones become weak and brittle. Treatment typically involves lifestyle modifications such as exercise and dietary changes, along with medications like bisphosphonates or hormone therapy in more severe cases.       

Osteopenia Treatment Market Dynamics

Drivers

• Advancements in Diagnostic Technologies

Technological advancements in bone density scanning and diagnostic tools have revolutionized the early detection and monitoring of osteopenia, thereby driving significant growth in the market. These advancements, including dual-energy X-ray absorptiometry (DEXA) and quantitative ultrasound (QUS), enable healthcare providers to accurately assess bone density levels, diagnose osteopenia at earlier stages, and monitor changes over time. This enhanced diagnostic capability not only improves patient outcomes by enabling timely intervention but also expands the market by increasing the overall demand for osteopenia treatments. 

• Impact of the Aging Population

Aging is associated with physiological changes in bone structure and density, leading to a higher susceptibility to osteopenia and its progression to osteoporosis. With older individuals experiencing a decline in bone mass and strength, there is an amplified need for effective treatments to mitigate the risks of fractures and other complications associated with bone frailty. For instance, in February 2023, the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO) agreed to create a strategic plan addressing bone health and aging. They aim to promote a public health strategy aimed at preventing fractures in elderly individuals. This demographic shift not only underscores the growing demand for osteopenia treatments but also emphasizes the importance of healthcare strategies focused on maintaining bone health and quality of life in elderly populations worldwide.

• Focus on Combination Therapies

The development of combination therapies that address multiple aspects of bone health, such as bone formation and resorption, while minimizing side effects presents a promising opportunity in the osteopenia treatment market. These therapies may include a combination of medications, dietary supplements, and lifestyle modifications tailored to individual patient needs. By targeting different mechanisms of bone metabolism simultaneously with alternative treatment for osteopenia, combination therapies aim to improve treatment efficacy and patient outcomes, thereby expanding market potential and meeting the diverse needs of patients with osteopenia.

Opportunities

• Lifestyle Modifications and Preventive Care

There is a growing emphasis on preventive healthcare measures, including lifestyle modifications such as regular exercise, a balanced diet, and adequate intake of calcium and vitamin D, which play a crucial role in supporting bone health and preventing osteopenia. These lifestyle interventions not only promote overall well-being but also reduce the risk of bone density disorders like osteopenia. As public awareness about the importance of these preventive measures increases, so does the demand for osteopenia treatments, driving market growth and creating opportunities for healthcare providers to offer comprehensive bone health management strategies.            

• Patient Education and Engagement

Enhanced patient education programs and initiatives aimed at improving treatment adherence and outcomes are critical for driving market growth in osteopenia treatment. Educating patients about the importance of medication adherence, lifestyle modifications, and regular follow-up visits empowers them to actively participate in their care, leading to better treatment compliance and overall satisfaction. By fostering patient engagement through personalized education and support, healthcare providers can enhance patient outcomes, reduce healthcare costs associated with non-adherence, and capitalize on opportunities for market expansion.

Restraints/Challenges

• High Treatment Costs 

The cost of osteopenia treatments, encompassing medications, diagnostic procedures like bone density scans, and ongoing management, can pose a significant barrier to market growth. High treatment costs may deter patients from seeking timely diagnosis and treatment, particularly in regions with limited healthcare resources or inadequate insurance coverage for bone health-related expenses.  

• Potential Side Effects of Medications

Concerns over potential side effects associated with osteopenia treatment medications, such as bisphosphonates, including gastrointestinal disturbances and osteonecrosis of the jaw, may influence patient adherence and treatment uptake. These side effects can lead to patient hesitancy or discontinuation of therapy, impacting treatment outcomes and overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In March 2024, Bone Health Technologies (BHT) secured a $5 million funding round aimed at advancing care for individuals with low bone density. This funding round attracted investments from Esplanade Ventures, Berkeley Catalyst Fund, and Terumo Medical, a prominent figure in medical technology globally. The funding infusion comes at a pivotal moment as BHT approaches the final stages of obtaining de novo FDA clearance for its Osteoboost vibration wearable
• In January 2024, Bone Health Technologies, a leader in bone health solutions, unveiled Osteoboost following FDA clearance. This innovative device represents the first non-pharmacological prescription treatment for postmenopausal women diagnosed with osteopenia. The wearable belt administers precise, calibrated vibrations to the lumbar spine and hips, aiming to mitigate the decrease in bone strength and density. The approval of Osteoboost introduces a groundbreaking therapeutic option for low bone density, representing a milestone in women's health advancements

Osteopenia Treatment Market Scope

The market is segmented on the basis of type, route of administration, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Bisphosphonates
• Calcitonin
• Hormone Therapy
• Parathyroid Hormone Related Therapy (PTHrP) Analog
• Selective Estrogen Receptor Modulator
• Others

Route of Administration

• Oral
• Injectables
• Others

Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others

Osteopenia Treatment Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, type, route of administration, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

북미는 강력한 경쟁 환경에 기여하는 저명한 주요 업체가 있기 때문에 시장을 지배할 것으로 예상됩니다. 이 지역은 다양한 환자 요구에 맞는 광범위한 치료 옵션의 혜택을 누리고 있으며, 첨단 의료 인프라와 전문 치료 시설로 유명한 잘 정립된 의료 부문의 지원을 받고 있습니다.            

아시아 태평양 지역은 연구 개발에 대한 노력 증가, 의료 인프라에 대한 투자 증가, 치료 옵션에 대한 수요 증가, 인구 고령화로 인해 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

의료 인프라 성장 설치 기반 및 신기술 침투

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 시장에 대한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 골다공증 치료 시장 점유율 분석

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 알러간 주식회사(아일랜드)
• 암젠 주식회사(미국)
• 액타비스 주식회사(아일랜드)
• 엘리 릴리 앤드 컴퍼니(미국)
• F. 호프만 라 로슈 유한회사(스위스)
• GlaxoSmithKline Pharmaceutical Ltd. (영국)
• Merck & Co AG(스위스)
• 노바티스 AG(스위스)
• Novo Nordisk A/S(덴마크)
• 파이저 주식회사(미국)
• Teva Pharmaceuticals Industries Ltd. (이스라엘)

SKU-63918